retatrutide phase 2 nejm weight loss 48 weeks 2023 percent Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 The loudest people online are

Unlike currently available GLP-1 drugs (glucagon-like peptide 1) including semaglutide, sold as Ozempic and Wegovy, aleniglipron is a small-molecule drug that is taken orally and is currently in development for the treatment of obesity

[Perkovic FLOW, NEJM 2024] STEP 1 Extension (Discontinuation Data) After stopping semaglutide, participants regained approximately two-thirds of lost weight within one year

Its hard to know if retatrutide has more side effects [compared with other obesity drugs] until you do studies comparing the medications head-to-head, Jay says

Intriguingly, in our studies, hypothalamic CAMK2 expression was upregulated by GLP1/E

Aesthetics: Losing facial fat + losing facial muscle = the gaunt look often called Ozempic Face. Longevity: For our older readers, muscle is the organ of longevity

Pregnant patients or those planning conception within six months are also excluded